GlassScriptPhysician profile
Calvin Parker
NPI 1073654976
$8,054.70
in general payments reported to CMS, 2019-2025
41 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $703 · 2021: $1,404 · 2022: $1,306 · 2023: $1,148 · 2024: $1,342 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,946 · Education: $29.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,945.64 |
| Education | $29.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,613.28 | 2019-2025 | |
| Janssen Biotech, INC. | $1,047.45 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $740.11 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $432.56 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $286.03 | 2022-2025 | |
| Ardelyx, INC. | $268.96 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $254.97 | 2020-2024 | |
| Intercept Pharmaceuticals, INC. | $238.27 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $232.39 | 2024-2025 | Iqirvo, Bylvay |
| Amgen INC. | $230.42 | 2020-2023 | Avsola, Amjevita |
| Pfizer INC. | $206.68 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $159.38 | 2019-2024 | Dificid, Zinplava |
| Boston Scientific Corporation | $120.94 | 2021 | |
| Nestle Healthcare Nutrition INC. | $120.22 | 2020-2023 | |
| Braintree Laboratories, INC. | $108.40 | 2019-2024 | Suflave, Sutab |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $94.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $90.44 | 2024-2025 | Dupixent |
| Daiichi Sankyo INC. | $83.92 | 2019-2024 | Injectafer |
| Qol Medical, LLC | $76.04 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $68.09 | 2024-2025 | Omvoh |
| Celgene Corporation | $64.09 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $57.72 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $54.61 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $50.78 | 2024-2025 | Vowst |
| Evoke Pharma, INC. | $41.64 | 2020-2021 | |
| Redhill Biopharma INC. | $31.63 | 2020-2021 | |
| Celltrion USA INC. | $29.78 | 2024 | Zymfentra |
| Allergan, INC. | $23.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.25 | 2025 | Rebyota |
| Fresenius Kabi USA, LLC | $21.76 | 2024 | Idacio |
| Medtronic, INC. | $20.73 | 2021 | |
| Sumitomo Pharma America, INC. | $18.75 | 2024 | Gemtesa |
| Gilead Sciences, INC. | $18.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.30 | 2023 | Cyltezo |
| Exact Sciences Corporation | $17.37 | 2023 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $16.99 | 2023 | Givlaari |
| Shionogi INC | $16.31 | 2019 | |
| Capsovision, INC. | $14.72 | 2024 | Capsocam Plus |
| Shire North American Group INC | $14.26 | 2019 | |
| Endogastric Solutions, INC | $13.94 | 2024 | Esophyx |
| Organon LLC | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.